Brii Biosciences Limited will convene its 2026 annual general meeting (AGM) online via the Vistra eVoting Portal at 8:00 a.m. (Hong Kong time) on Tuesday, 16 June 2026. Shareholders will be asked to approve the following key items:

1. 2025 Financial Statements • Adoption of the audited consolidated results for the financial year ended 31 December 2025, together with the directors’ and auditor’s reports.

2. Board Composition and Remuneration • Re-election of Executive Director Dr. Zhi Hong. • Re-election of Independent Non-executive Directors Dr. Martin J Murphy Jr. and Dr. Taiyin Yang. • Authorisation for the board to determine directors’ remuneration.

3. Auditor • Re-appointment of Deloitte Touche Tohmatsu as external auditor until the next AGM and authorisation for the board to fix its remuneration.

4. Share Capital Mandates • General mandate permitting the board to allot, issue or deal with shares up to 20% of the company’s issued share capital (excluding any treasury shares) as at the date of the AGM. • Authority to repurchase shares on the Stock Exchange or other recognised exchanges up to 10% of issued share capital (excluding any treasury shares). • Extension of the issuance mandate by the amount of shares actually bought back under the repurchase mandate, capped at an additional 10% of issued share capital.

Key Administrative Dates • Register of members closure: Thursday, 11 June 2026 to Tuesday, 16 June 2026 (both days inclusive). • Share transfer deadline for AGM eligibility: 4:30 p.m. on Wednesday, 10 June 2026. • Proxy submission deadline: 8:00 a.m. on Sunday, 14 June 2026.

Meeting Format The AGM will be conducted exclusively online. Shareholders may vote and submit questions in real time through the Vistra eVoting Portal or appoint proxies— including the AGM chairman— to vote on their behalf.

All resolutions will be decided by poll, and results will be published on the company’s website (www.briibio.com) and the Hong Kong Stock Exchange website (www.hkexnews.hk).

As of the notice date (24 April 2026), the board consists of Executive Directors Dr. Zhi Hong and Dr. Ankang Li, and five Independent Non-executive Directors: Dr. Martin J Murphy Jr., Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang.